Seeking Alpha

QualityStocks'  Instablog

Send Message
QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Announces Publication Of Positive Results For Prostate Cancer Immunotherapy Study 0 comments
    Jun 13, 2012 5:25 PM | about stocks: ADXS

    Advaxis, clinical-stage developer of next-generation immunotherapies for cancer and infectious diseases, today announced the publication of research with the company's ADXS-PSA (ADXS31-142), which demonstrated significant tumor regression in prostate cancer in preclinical study.

    The study was conducted to determine if the combination of ADXS-PSA immunotherapy and radiation therapy could improve upon the efficacy of either immunotherapy as stand-alone treatment or radiation therapy as a stand-alone in the treatment of mice bearing PSA-expressing TPSA23 tumors, a preclinical model of prostate cancer.

    The study showed that the combination of ADXS-PSA immunotherapy and radiation therapy resulted in complete regression of established tumors in 60 percent of mice vs. 10 percent complete regression in either of the treatments alone.

    This research was conducted in collaboration with Dr. Chandan Guha and his laboratory at Montefiore Medical Center, Bronx, NY, and was e-published ahead of print in the journal of Cancer Immunology Immunotherapy in the paper titled "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer."

    "ADXS-PSA continues to demonstrate activity in models of prostate cancer, confirming our decision to move this construct into clinical development. The potential synergy of ADXS-PSA and radiotherapy observed in this study suggests that ADXS-PSA might be combined with other therapies that show efficacy in this type of tumor," Dr. John Rothman, EVP of Science and Operations at Advaxis stated in the press release.

    For more information visit

    Please see disclaimer on the QualityStocks website:

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.